Migraine in Electrohypersensitive Patients

June 23, 2023 updated by: University Hospital, Montpellier

Prevalence of Migraine Disease in Electrohypersensitive Patients

The investigators propose here by the use of the French version of the migraine disease screening questionnaire (ID Migraine ™) to study the prevalence of migraine disease in a population of electrohypersensitive patients

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

317

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Montpellier, France, 34295
        • UHMontpellier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

An adult declaring himself electrohypersensitive

Description

Inclusion criteria:

  • Informed Consent
  • 18 years or older at the time of informed consent

With all these criteria :

  • the perception by the subjects of various non-specific functional symptoms
  • the absence of clinical and biological evidence to explain the symptoms
  • the attribution by the subjects themselves of these symptoms to exposure to electromagnetic fields, which are themselves diverse
  • the symptoms are chronic (more than 3 months)
  • the symptoms appear during an exposure to a source of electromagnetic radiation and cease after the exposure is stopped
  • the symptoms are reproducible

Exclusion criteria:

- age under 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Possible migraine attack
Time Frame: 12 months
With the number of positive response to the French version of the migraine disease screening questionnaire, we are looking for the patients declaring themselves electrohypersensitive if they have had headaches in the last 12 months with characteristics that could evoke a migraine attack.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Investigators

  • Principal Investigator: Frédéric GRECO, University Hospital, Montpellier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2021

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

January 30, 2022

Study Registration Dates

First Submitted

April 10, 2021

First Submitted That Met QC Criteria

April 10, 2021

First Posted (Actual)

April 14, 2021

Study Record Updates

Last Update Posted (Actual)

June 26, 2023

Last Update Submitted That Met QC Criteria

June 23, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RECHMPL21_0250

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

NC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe